DUX4 and cancer: In this context, DUX4 drives an aberrant program of embryonic gene expression and provides a distinct advantage to cancer cells, allowing suppression of MHC class I-dependent antigen presentation, immune evasion, and resistance to immune checkpoint blockade [13].